Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors.

Publication ,  Journal Article
Anderson, JE; Appelbaum, FR; Schoch, G; Gooley, T; Anasetti, C; Bensinger, WI; Bryant, E; Buckner, CD; Chauncey, TR; Clift, RA; Doney, K ...
Published in: Blood
January 1, 1996

From 1990 to 1993 we performed a prospective study of busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) in 30 patients with refractory anemia (RA) undergoing related (n = 17) or unrelated (n = 13) donor marrow transplantation. Nineteen patients survive disease free (63% 3-year actuarial disease-free survival [DFS]) and no patient relapsed. These results were compared to those of 38 historical controls with RA treated with cyclophosphamide and total body irradiation, of whom 22 are disease-free survivors and 1 relapsed. After correcting for significant variables between the two treatment groups, we found no statistically significant difference in outcome based on preparative regimen. Combining data from these 68 patients plus 2 additional patients with RA treated before 1993 with busulfan and cyclophosphamide, we identified four variables independently associated with improved survival: younger age, shorter disease duration, lower neutrophil count pretransplant, and lower hematocrit pretransplant. We also found that 15 patients 40 to 55 years of age had a 46% 3-year actuarial DFS and 26 patients receiving unrelated or mismatched related donor marrow had a 50% 3-year actuarial DFS. We conclude that there does not appear to be any significant difference in outcome based on preparative regimen in this patient population. In addition, allogeneic bone marrow transplantation may be a reasonable approach to therapy of RA early after diagnosis. However, whether early intervention with transplantation prolongs survival over that expected without transplantation cannot be ascertained with certainty from available data.

Duke Scholars

Published In

Blood

ISSN

0006-4971

Publication Date

January 1, 1996

Volume

87

Issue

1

Start / End Page

51 / 58

Location

United States

Related Subject Headings

  • Whole-Body Irradiation
  • Treatment Outcome
  • Survival Analysis
  • Prognosis
  • Middle Aged
  • Male
  • Leukocyte Count
  • Immunology
  • Humans
  • Hematocrit
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Anderson, J. E., Appelbaum, F. R., Schoch, G., Gooley, T., Anasetti, C., Bensinger, W. I., … Storb, R. (1996). Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood, 87(1), 51–58.
Anderson, J. E., F. R. Appelbaum, G. Schoch, T. Gooley, C. Anasetti, W. I. Bensinger, E. Bryant, et al. “Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors.Blood 87, no. 1 (January 1, 1996): 51–58.
Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996 Jan 1;87(1):51–8.
Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey TR, Clift RA, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996 Jan 1;87(1):51–58.

Published In

Blood

ISSN

0006-4971

Publication Date

January 1, 1996

Volume

87

Issue

1

Start / End Page

51 / 58

Location

United States

Related Subject Headings

  • Whole-Body Irradiation
  • Treatment Outcome
  • Survival Analysis
  • Prognosis
  • Middle Aged
  • Male
  • Leukocyte Count
  • Immunology
  • Humans
  • Hematocrit